Trade Thermo Fisher Scientific - TMO CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Spread | 0.62 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Thermo Fisher Scientific Inc ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Prev. Close* | 554.37 |
Open* | 552.62 |
1-Year Change* | -6.16% |
Day's Range* | 546.62 - 552.62 |
52 wk Range | 415.60-609.85 |
Average Volume (10 days) | 2.02M |
Average Volume (3 months) | 40.15M |
Market Cap | 210.35B |
P/E Ratio | 35.65 |
Shares Outstanding | 386.37M |
Revenue | 43.42B |
EPS | 15.27 |
Dividend (Yield %) | 0.25715 |
Beta | 0.80 |
Next Earnings Date | Jan 31, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 16, 2024 | 554.37 | -2.47 | -0.44% | 556.84 | 558.31 | 551.06 |
Apr 15, 2024 | 557.33 | -10.57 | -1.86% | 567.90 | 569.97 | 553.76 |
Apr 12, 2024 | 565.03 | -3.05 | -0.54% | 568.08 | 572.31 | 561.03 |
Apr 11, 2024 | 574.17 | -1.68 | -0.29% | 575.85 | 580.22 | 570.94 |
Apr 10, 2024 | 573.31 | -2.66 | -0.46% | 575.97 | 579.55 | 567.98 |
Apr 9, 2024 | 589.01 | 8.14 | 1.40% | 580.87 | 589.46 | 580.87 |
Apr 8, 2024 | 578.77 | 3.82 | 0.66% | 574.95 | 581.09 | 571.19 |
Apr 5, 2024 | 578.46 | 13.41 | 2.37% | 565.05 | 583.57 | 565.05 |
Apr 4, 2024 | 568.44 | -6.54 | -1.14% | 574.98 | 580.96 | 567.95 |
Apr 3, 2024 | 575.63 | 6.51 | 1.14% | 569.12 | 577.75 | 569.12 |
Apr 2, 2024 | 571.50 | 2.57 | 0.45% | 568.93 | 572.09 | 565.52 |
Apr 1, 2024 | 576.58 | -4.27 | -0.74% | 580.85 | 580.86 | 572.55 |
Mar 28, 2024 | 580.37 | 4.44 | 0.77% | 575.93 | 582.13 | 575.66 |
Mar 27, 2024 | 579.31 | 11.94 | 2.10% | 567.37 | 579.61 | 567.37 |
Mar 26, 2024 | 568.69 | -1.98 | -0.35% | 570.67 | 574.81 | 567.50 |
Mar 25, 2024 | 572.80 | -8.76 | -1.51% | 581.56 | 582.95 | 570.53 |
Mar 22, 2024 | 582.19 | -3.01 | -0.51% | 585.20 | 588.32 | 579.26 |
Mar 21, 2024 | 583.74 | 8.60 | 1.50% | 575.14 | 586.80 | 575.14 |
Mar 20, 2024 | 579.84 | -0.32 | -0.06% | 580.16 | 581.07 | 575.46 |
Mar 19, 2024 | 581.14 | 1.21 | 0.21% | 579.93 | 583.95 | 576.10 |
Thermo Fisher Scientific Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, April 24, 2024 | ||
Time (UTC) 12:30 | Country US
| Event Q1 2024 Thermo Fisher Scientific Inc Earnings Call Q1 2024 Thermo Fisher Scientific Inc Earnings CallForecast -Previous - |
Time (UTC) 12:30 | Country US
| Event Q1 2024 Thermo Fisher Scientific Inc Earnings Release Q1 2024 Thermo Fisher Scientific Inc Earnings ReleaseForecast -Previous - |
Wednesday, May 22, 2024 | ||
Time (UTC) 13:00 | Country US
| Event Thermo Fisher Scientific Inc Annual Shareholders Meeting Thermo Fisher Scientific Inc Annual Shareholders MeetingForecast -Previous - |
Thursday, May 23, 2024 | ||
Time (UTC) 17:00 | Country US
| Event Thermo Fisher Scientific Inc Annual Shareholders Meeting Thermo Fisher Scientific Inc Annual Shareholders MeetingForecast -Previous - |
Wednesday, July 24, 2024 | ||
Time (UTC) 12:30 | Country US
| Event Q2 2024 Thermo Fisher Scientific Inc Earnings Release Q2 2024 Thermo Fisher Scientific Inc Earnings ReleaseForecast -Previous - |
Monday, October 7, 2024 | ||
Time (UTC) 10:59 | Country US
| Event Q4 2024 Thermo Fisher Scientific Inc Earnings Release Q4 2024 Thermo Fisher Scientific Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 44915 | 39211 | 32218 | 25542 | 24358 |
Revenue | 44915 | 39211 | 32218 | 25542 | 24358 |
Cost of Revenue, Total | 25944 | 19573 | 16231 | 14213 | 13499 |
Gross Profit | 18971 | 19638 | 15987 | 11329 | 10859 |
Total Operating Expense | 36548 | 29950 | 24424 | 21132 | 20575 |
Selling/General/Admin. Expenses, Total | 8934 | 7816 | 6940 | 6082 | 6028 |
Research & Development | 1471 | 1406 | 1181 | 1003 | 967 |
Unusual Expense (Income) | 140 | 1108 | 89 | -167 | 79 |
Operating Income | 8367 | 9261 | 7794 | 4410 | 3783 |
Interest Income (Expense), Net Non-Operating | -548 | -427 | -569 | -408 | -528 |
Other, Net | 16 | 7 | 68 | 7 | |
Net Income Before Taxes | 7835 | 8841 | 7225 | 4070 | 3262 |
Net Income After Taxes | 7132 | 7732 | 6375 | 3704 | 3055 |
Net Income Before Extra. Items | 6950 | 7725 | 6375 | 3704 | 3055 |
Total Extraordinary Items | 0 | -8 | -117 | ||
Net Income | 6950 | 7725 | 6375 | 3696 | 2938 |
Income Available to Common Excl. Extra. Items | 6950 | 7725 | 6375 | 3704 | 3055 |
Income Available to Common Incl. Extra. Items | 6950 | 7725 | 6375 | 3696 | 2938 |
Diluted Net Income | 6950 | 7725 | 6375 | 3696 | 2938 |
Diluted Weighted Average Shares | 394 | 397 | 399 | 403 | 406 |
Diluted EPS Excluding Extraordinary Items | 17.6396 | 19.4584 | 15.9774 | 9.19107 | 7.52463 |
Dividends per Share - Common Stock Primary Issue | 1.16 | 1 | 0.85 | 0.74 | 0.66 |
Diluted Normalized EPS | 18.0254 | 21.9169 | 16.1875 | 8.85233 | 7.73455 |
Interest Expense (Income) - Net Operating | -17 | 1 | 2 | ||
Other Operating Expenses, Total | 59 | 47 | |||
Minority Interest | -10 | -3 | |||
Equity In Affiliates | -172 | -4 |
Sep 2023 | Jul 2023 | Apr 2023 | Dec 2022 | Oct 2022 | |
---|---|---|---|---|---|
Total revenue | 10574 | 10687 | 10710 | 11450 | 10677 |
Revenue | 10574 | 10687 | 10710 | 11450 | 10677 |
Cost of Revenue, Total | 6145 | 6436 | 6570 | 6844 | 6375 |
Gross Profit | 4429 | 4251 | 4140 | 4606 | 4302 |
Total Operating Expense | 8710 | 9109 | 9147 | 9589 | 8967 |
Selling/General/Admin. Expenses, Total | 1578 | 2145 | 2119 | 2240 | 2208 |
Research & Development | 319 | 345 | 346 | 391 | 351 |
Unusual Expense (Income) | 84 | 183 | 112 | 55 | 33 |
Operating Income | 1864 | 1578 | 1563 | 1861 | 1710 |
Interest Income (Expense), Net Non-Operating | -113 | -148 | -198 | -144 | -118 |
Other, Net | 14 | 0 | -2 | 60 | 9 |
Net Income Before Taxes | 1765 | 1430 | 1363 | 1777 | 1601 |
Net Income After Taxes | 1712 | 1378 | 1317 | 1604 | 1570 |
Net Income Before Extra. Items | 1715 | 1361 | 1289 | 1576 | 1495 |
Net Income | 1715 | 1361 | 1289 | 1576 | 1495 |
Income Available to Common Excl. Extra. Items | 1715 | 1361 | 1289 | 1576 | 1495 |
Income Available to Common Incl. Extra. Items | 1715 | 1361 | 1289 | 1576 | 1495 |
Diluted Net Income | 1715 | 1361 | 1289 | 1576 | 1495 |
Diluted Weighted Average Shares | 388 | 388 | 388 | 392 | 395 |
Diluted EPS Excluding Extraordinary Items | 4.4201 | 3.50773 | 3.32216 | 4.02041 | 3.78481 |
Dividends per Share - Common Stock Primary Issue | 0.35 | 0.35 | 0.3 | 0.3 | 0.3 |
Diluted Normalized EPS | 4.6176 | 3.9672 | 3.67828 | 4.15857 | 3.92135 |
Other Operating Expenses, Total | 59 | ||||
Minority Interest | 20 | -1 | -3 | 2 | -3 |
Equity In Affiliates | -17 | -16 | -25 | -30 | -72 |
Depreciation / Amortization | 584 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 25229 | 20113 | 21957 | 11893 | 10625 |
Cash and Short Term Investments | 8526 | 4477 | 10353 | 2436 | 2134 |
Cash & Equivalents | 8524 | 4477 | 10325 | 2399 | 2103 |
Short Term Investments | 2 | 28 | 37 | 31 | |
Total Receivables, Net | 9427 | 8945 | 6472 | 4952 | 4136 |
Accounts Receivable - Trade, Net | 9427 | 8945 | 6472 | 4952 | 4136 |
Total Inventory | 5634 | 5051 | 4029 | 3370 | 3005 |
Other Current Assets, Total | 1642 | 1640 | 1103 | 1135 | 1350 |
Total Assets | 97154 | 95123 | 69052 | 58381 | 56232 |
Property/Plant/Equipment, Total - Net | 10873 | 9864 | 6687 | 5448 | 4165 |
Property/Plant/Equipment, Total - Gross | 15862 | 14124 | 10352 | 8463 | 6820 |
Accumulated Depreciation, Total | -4989 | -4260 | -3665 | -3015 | -2655 |
Goodwill, Net | 41196 | 41924 | 26041 | 25714 | 25347 |
Intangibles, Net | 17442 | 20113 | 12685 | 14014 | 14978 |
Other Long Term Assets, Total | 2352 | 3087 | 1682 | 1312 | 1117 |
Total Current Liabilities | 17010 | 13436 | 10304 | 6197 | 6147 |
Accounts Payable | 3381 | 2867 | 2175 | 1920 | 1615 |
Accrued Expenses | 5433 | 5377 | 4098 | 2674 | 2436 |
Notes Payable/Short Term Debt | 310 | 2522 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 5269 | 15 | 2628 | 676 | 1271 |
Other Current Liabilities, Total | 2617 | 2655 | 1403 | 927 | 825 |
Total Liabilities | 53176 | 54330 | 34545 | 28706 | 28646 |
Total Long Term Debt | 28909 | 32333 | 19107 | 17076 | 17719 |
Long Term Debt | 28909 | 32333 | 19107 | 17076 | 17719 |
Deferred Income Tax | 2849 | 3837 | 1794 | 2192 | 2265 |
Other Liabilities, Total | 4238 | 4540 | 3340 | 3241 | 2515 |
Total Equity | 43978 | 40793 | 34507 | 29675 | 27586 |
Common Stock | 441 | 439 | 437 | 434 | 432 |
Additional Paid-In Capital | 16743 | 16174 | 15579 | 15064 | 14621 |
Retained Earnings (Accumulated Deficit) | 41910 | 35431 | 28116 | 22092 | 18696 |
Treasury Stock - Common | -12017 | -8922 | -6818 | -5236 | -3665 |
Unrealized Gain (Loss) | -33 | -35 | -91 | -71 | -52 |
Other Equity, Total | -3066 | -2294 | -2716 | -2608 | -2446 |
Total Liabilities & Shareholders’ Equity | 97154 | 95123 | 69052 | 58381 | 56232 |
Total Common Shares Outstanding | 390.511 | 394.435 | 396.671 | 398.74 | 402.122 |
Long Term Investments | 55 | 22 | |||
Minority Interest | 170 | 184 | |||
Note Receivable - Long Term | 7 |
Sep 2023 | Jul 2023 | Apr 2023 | Dec 2022 | Oct 2022 | |
---|---|---|---|---|---|
Total Current Assets | 23092 | 19995 | 20209 | 25229 | 19299 |
Cash and Short Term Investments | 6151 | 3133 | 3482 | 8526 | 2941 |
Cash & Equivalents | 6151 | 3133 | 3482 | 8524 | 2919 |
Short Term Investments | 2 | 22 | |||
Total Receivables, Net | 9835 | 9486 | 9297 | 9427 | 8919 |
Accounts Receivable - Trade, Net | 9835 | 9486 | 9297 | 9427 | 8919 |
Total Inventory | 5404 | 5655 | 5664 | 5634 | 5722 |
Other Current Assets, Total | 1702 | 1721 | 1766 | 1642 | 1717 |
Total Assets | 97057 | 94105 | 94658 | 97154 | 90536 |
Property/Plant/Equipment, Total - Net | 9167 | 9292 | 9354 | 9280 | 8628 |
Goodwill, Net | 43583 | 43273 | 43140 | 41196 | 40488 |
Intangibles, Net | 17091 | 17437 | 17972 | 17442 | 17813 |
Other Long Term Assets, Total | 4119 | 4102 | 3975 | 4000 | 4299 |
Total Current Liabilities | 14158 | 14112 | 15884 | 17010 | 11118 |
Accounts Payable | 2508 | 2423 | 2798 | 3381 | 2471 |
Accrued Expenses | 4308 | 4285 | 4302 | 5433 | 5068 |
Notes Payable/Short Term Debt | 0 | 500 | 824 | 310 | 0 |
Current Port. of LT Debt/Capital Leases | 4795 | 4314 | 5298 | 5269 | 1010 |
Other Current Liabilities, Total | 2547 | 2590 | 2662 | 2617 | 2569 |
Total Liabilities | 51729 | 50353 | 52401 | 53176 | 46987 |
Total Long Term Debt | 30489 | 29194 | 29135 | 28909 | 28150 |
Long Term Debt | 30489 | 29194 | 29135 | 28909 | 28150 |
Deferred Income Tax | 2620 | 2842 | 2976 | 2849 | 3140 |
Other Liabilities, Total | 4326 | 4042 | 4230 | 4238 | 4401 |
Total Equity | 45328 | 43752 | 42257 | 43978 | 43549 |
Common Stock | 442 | 441 | 441 | 441 | 440 |
Additional Paid-In Capital | 17165 | 17030 | 16889 | 16743 | 16596 |
Retained Earnings (Accumulated Deficit) | 45869 | 44289 | 43064 | 41910 | 40452 |
Treasury Stock - Common | -15121 | -15084 | -15083 | -12017 | -11011 |
Unrealized Gain (Loss) | -28 | -29 | -30 | -33 | -33 |
Other Equity, Total | -2999 | -2895 | -3024 | -3066 | -2895 |
Total Liabilities & Shareholders’ Equity | 97057 | 94105 | 94658 | 97154 | 90536 |
Total Common Shares Outstanding | 386.372 | 385.95 | 385.721 | 390.511 | 392.196 |
Property/Plant/Equipment, Total - Gross | |||||
Accumulated Depreciation, Total | |||||
Minority Interest | 136 | 163 | 176 | 170 | 178 |
Note Receivable - Long Term | 5 | 6 | 8 | 7 | 9 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 6960 | 7728 | 6375 | 3696 | 2938 |
Cash From Operating Activities | 9154 | 9312 | 8289 | 4973 | 4543 |
Cash From Operating Activities | 986 | 831 | 658 | 564 | 2267 |
Deferred Taxes | -995 | -647 | -552 | -302 | -379 |
Non-Cash Items | 857 | 1187 | 536 | -33 | 287 |
Changes in Working Capital | -1049 | -1548 | -395 | -665 | -570 |
Cash From Investing Activities | -2159 | -21932 | -1510 | -1487 | -1253 |
Capital Expenditures | -2243 | -2523 | -1474 | -926 | -758 |
Other Investing Cash Flow Items, Total | 84 | -19409 | -36 | -561 | -495 |
Cash From Financing Activities | -2810 | 6581 | 959 | -3118 | -2237 |
Financing Cash Flow Items | -9 | -91 | -147 | -69 | -51 |
Total Cash Dividends Paid | -455 | -395 | -337 | -297 | -266 |
Issuance (Retirement) of Stock, Net | -3000 | -1844 | -1304 | -1347 | -364 |
Issuance (Retirement) of Debt, Net | 654 | 8911 | 2747 | -1405 | -1556 |
Foreign Exchange Effects | -139 | 194 | 176 | -63 | -297 |
Net Change in Cash | 4046 | -5845 | 7914 | 305 | 756 |
Cash Taxes Paid | 1234 | 2182 | 1324 | 896 | 591 |
Cash Interest Paid | 667 | 555 | 471 | 790 | 687 |
Amortization | 2395 | 1761 | 1667 | 1713 |
Apr 2023 | Dec 2022 | Oct 2022 | Jul 2022 | Apr 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 1292 | 6960 | 5386 | 3888 | 2220 |
Cash From Operating Activities | 729 | 9154 | 5667 | 3730 | 2202 |
Cash From Operating Activities | 253 | 986 | 730 | 486 | 250 |
Amortization | 606 | 2395 | 1803 | 1209 | 609 |
Deferred Taxes | -146 | -995 | -862 | -601 | -339 |
Non-Cash Items | 257 | 857 | 701 | 472 | 337 |
Changes in Working Capital | -1533 | -1049 | -2091 | -1724 | -875 |
Cash From Investing Activities | -3142 | -2159 | -1634 | -1089 | -670 |
Capital Expenditures | -458 | -2243 | -1693 | -1146 | -640 |
Other Investing Cash Flow Items, Total | -2684 | 84 | 59 | 57 | -30 |
Cash From Financing Activities | -2593 | -2810 | -5201 | -5050 | -3145 |
Financing Cash Flow Items | 20 | -9 | -86 | -48 | -36 |
Total Cash Dividends Paid | -117 | -455 | -338 | -220 | -103 |
Issuance (Retirement) of Stock, Net | -3000 | -3000 | -1943 | -1949 | -1998 |
Issuance (Retirement) of Debt, Net | 504 | 654 | -2834 | -2833 | -1008 |
Foreign Exchange Effects | -31 | -139 | -389 | -177 | -99 |
Net Change in Cash | -5037 | 4046 | -1557 | -2586 | -1712 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Thermo Fisher Company profile
Thermo Fisher Scientific Inc. (TMO) is a supplier of scientific laboratory products, instruments, software and other tools. The company was formed in a tax-free stock-for-stock merger of Thermo Electron Corporation with Fisher Scientific International Inc. in 2006.
The company provides services through various brands including Thermo Fishers, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.
Thermo Fisher works on accelerating life sciences research by solving complex analytical challenges. Its products aim to increase productivity in laboratories and improve patient health through diagnostics and therapy development.
The four segments that Thermo Fisher Scientific caters to are industrial and applied research, diagnostics and healthcare, academic and government research, and pharmaceuticals and biotechnology.
As of June 2022, Thermo Fisher has developed Orbitrap Exploris MX mass spectrometer, cell therapy workflow solutions, Oncomine Dx Target Test and several other solutions that aim to make the diagnosis of infections and diseases easier and enable production of drugs and vaccines.
Thermo Fisher Scientific Inc. stock is trading on the New York Stock Exchange (NYSE) under the ticker symbol TMO. You can follow live TMO stock movement and price history, and stay on top of the latest TMO share value at Capital.com.
Industry: | Advanced Medical Equipment & Technology (NEC) |
168 Third Avenue
WALTHAM
MASSACHUSETTS 02451
US
Income Statement
- Annual
- Quarterly
News
Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com